Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 15/20 | 0.54 |
| ▸ | CA2 | P00918 | 15/20 | 0.54 |
| ▸ | CA12 | O43570 | 13/20 | 0.54 |
| ▸ | CA9 | Q16790 | 13/20 | 0.54 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | PRF1 | P14222 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2634053 | 0.83 | CA1 (0.37) | CA1CA2CA12CA9CA4 | |
| SCHEMBL788789 | 0.83 | CA1 (0.37) | CA1CA2CA12CA9CA4 | |
| SCHEMBL12319229 | 0.83 | CA1 (0.40) | CA1CA2CA12CA9CA4 | |
| SCHEMBL10154049 | 0.80 | MAPT (0.44) | CA1CA2CA12CA9NPC1 | |
| SCHEMBL15882624 | 0.80 | MAPT (0.41) | CA1CA2CA12CA9NPC1 | |
| SCHEMBL4802533 | 0.75 | CA2 (0.53) | CA1CA2CA12CA9CA4 | |
| SCHEMBL8747108 | 0.71 | NPC1 (0.40) | NPC1RAB9A | |
| SCHEMBL29285931 | 0.69 | MEN1 (0.66) | NPC1RAB9APRF1 | |
| SCHEMBL1548721 | 0.68 | POLB (0.52) | CA1CA2CA12CA9CA4 | |
| SCHEMBL4109831 | 0.68 | KDM4E (0.60) | CA1CA2CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087527-A1 | NOVEL TRPM4 ANTAGONISTS AND MEDICAL USE THEREOF | Universitätsklinikum Hamburg-Eppendorf (DE) | 2026-04-30 | — | — | WO | claimed |
| EP-4733298-A1 | NOVEL TRPM4 ANTAGONISTS AND MEDICAL USE THEREOF | Universitätsklinikum Hamburg-Eppendorf (DE) | 2026-04-29 | — | — | EP | claimed |
| WO-2026087527-A1 | NOVEL TRPM4 ANTAGONISTS AND MEDICAL USE THEREOF | Universitätsklinikum Hamburg-Eppendorf (DE) | 2026-04-30 | — | — | WO | disclosed |
| EP-4733298-A1 | NOVEL TRPM4 ANTAGONISTS AND MEDICAL USE THEREOF | Universitätsklinikum Hamburg-Eppendorf (DE) | 2026-04-29 | — | — | EP | disclosed |
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080027012-A1 | BRIDGED CARBAMATE MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20080027012-A1 | BRIDGED CARBAMATE MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-01-31 | — | — | US | disclosed |
| WO-2008014221-A2 | BRIDGED CARBAMATE MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-7312201-B2 | Tetracyclic bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312201-B2 | Tetracyclic bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7291602-B2 | 11,12-lactone bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291602-B2 | 11,12-lactone bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| WO-2007115278-A2 | 3,6,11-TRICYCLOLIDE | ENANTA PHARMACEUTICALS, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027012-A1 | BRIDGED CARBAMATE MACROLIDES | HDAC6, SI, HDAC3 | CA1 2023/4885CA2 363/4885CA12 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.